Do you want to read an article? Please log in or register.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
Breast Cancer
RECOMMENDED
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
Breast Cancer
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials
Eur J Cancer
Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S
doi: 10.1016/j.ejca.2025.115225
RECOMMENDED
Breast Cancer
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N
doi: 10.1016/S1470-2045(25)00233-5
RECOMMENDED
Breast Cancer
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY
doi: 10.1016/S1470-2045(25)00545-5
RECOMMENDED
Breast Cancer
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Kirby AM, Finneran L, Griffin CL, Brunt AM, Cafferty FH, Alhasso A, Chan C, Haviland JS, Jefford ML, Sawyer EJ, Sydenham MA, Syndikus I, Tsang YM, Wheatley D, Yarnold JR, Coles CE, Bliss JM
doi: 10.1016/S1470-2045(25)00194-9
Lung, Respiratory and Thoracic Cancer
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Lung Cancer
Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K
doi: 10.1016/j.lungcan.2025.108109
Gynecologic Cancer
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
CA Cancer J Clin
Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N
doi: 10.3322/caac.70042
SABCS 2024
Breast Cancer